Joseph P. Hagan Sells 115,290 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Joseph P. Hagan sold 115,290 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $145,265.40. Following the sale, the chief executive officer now owns 222,572 shares of the company’s stock, valued at $280,440.72. The trade was a 34.12 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Regulus Therapeutics Stock Up 0.8 %

Shares of RGLS stock opened at $1.28 on Friday. The firm has a market capitalization of $83.84 million, a price-to-earnings ratio of -1.20 and a beta of 1.60. Regulus Therapeutics Inc. has a 12-month low of $1.08 and a 12-month high of $3.79. The firm has a fifty day moving average of $1.52 and a 200-day moving average of $1.58.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Research analysts expect that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.80.

Institutional Trading of Regulus Therapeutics

Several hedge funds have recently bought and sold shares of RGLS. Creative Planning acquired a new position in shares of Regulus Therapeutics in the third quarter valued at approximately $26,000. SG Americas Securities LLC bought a new stake in Regulus Therapeutics in the 3rd quarter valued at $33,000. Jane Street Group LLC acquired a new position in Regulus Therapeutics in the 3rd quarter worth $46,000. Rhumbline Advisers acquired a new stake in shares of Regulus Therapeutics in the 2nd quarter valued at about $136,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Regulus Therapeutics by 193.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 52,059 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.